Raman Pharma is a UK based MHRA and VMD Licensed Wholesaler supplying to the Human and Veterinary Market. We are a family run company ambitiously changing the face of the Pharmaceutical and Veterinary Market alike in order to serve the needs of our customers and their patients.
Our Philosophy and business are structured around the requirements of our customers and we are committed to giving them our upmost attention and care. We believe in delivering quality and value to our customers wherever they may be.
The Herbal Horse and Pet is a South African manufacturer of a very innovative range of supplements for horses, dogs and cats. Their philosophy of using a large number of different ingredients in small amounts mimics nature in that the healing effect of the ingredients is maximised while undesirable side-effects are minimised. These unique formulations, in conjunction with 21st century scientific research and techniques are what they call “cutting edge nature”.
They are manufactured in a GMP Compliant Factory and has a large following from riders and pet owners across the world. Please follow the link to the website – www.theherbalhorse.co.uk to see all the amazing blogs and the ability to purchase these products online. The Equine and Pet Range were introduced to the UK Market in September 2014 by Raman Pharma to give the UK a taste of the future in equine and companion animal nutritional supplements.
"Fantastic service, Really helpful & always able to source products that we need at very competitive prices. Would thoroughly recommend to any Veterinary Practice"
"Raman Pharma have been invaluable in sourcing drugs that are out of stock elsewhere. Delivery is rapid, costs are good and the customer service provided by Dhruv is excellent. I would definitely recommend this company and its services to others."
Community pharmacy contractors are now able to claim payment for being required by NHS England and NHS Improvement (NHSE&I) to open between 2pm to 5pm on the Early May Bank Holiday (Friday 8th May). Contractors must submit their claim for the £250 per hour payment using the Manage Your Service (MYS) portal between the 25th...
PSNC has raised concerns about the appropriateness of prescription switching during the COVID-19 pandemic with the Department of Health and Social Care (DHSC). Community pharmacy contractors have started to receive their FP34 Schedule of Payments relating to the dispensing of March 2020 – the month that the COVID-19 outbreak hit the UK – and many...
Last year, PSNC and the LPCs jointly funded an independent review into community pharmacy contractor support and representation. The aim of the review was to find ways to optimise LPC and PSNC working to ensure that the national network structure for contractor representation is working as efficiently as it can, is providing best value for...
The General Pharmaceutical Council (GPhC) has announced its intention to add current pre-registration trainees to the pharmacist register on a provisional basis. Postponements of the registration assessment scheduled for June and September 2020 as a result of the COVID-19 pandemic meant that the usual influx of new pharmacists would not be available to support the workforce...
The Department of Health and Social Care (DHSC) has today announced that the requirement to publish renewed Pharmaceutical Needs Assessments (PNAs) will be suspended for a year. PNAs are due to be renewed and published by Local Authority Health and Wellbeing Boards (HWBs) in April 2021. However, as most resources have been diverted to the...
A new campaign to help pharmacists and pharmacy students to prioritise their wellbeing has been launched by Pharmacist Support, the profession’s independent charity. The COVID-19 outbreak has presented an uncertain and unprecedented situation for the sector, putting pressure on all community pharmacy teams. It can be difficult for pharmacy staff to find time to prioritise their own needs so the ACTNow...
A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 13 Issue 10 May 2020) has been published and includes articles on: Coronavirus (COVID-19): new dedicated Yellow Card reporting site for medicines and medical devices Valproate Pregnancy Prevention Programme: temporary advice for management during coronavirus (COVID-19) Immunomodulatory drugs and pregnancy prevention: temporary...
Full details of the Government’s life assurance scheme for frontline healthcare workers have now been released. The scheme will make a payment of £60,000 to the estate of eligible individuals who die from COVID-19 contracted during their frontline essential work. The newly released information states the scheme will remain open until the relevant NHS workforce provisions...
COVID-19 guidance for commissioners and service providers for those dependent on drugs or alcohol has been published. The updated guidance highlights that people who misuse or are dependent on drugs and alcohol may also be at increased risk of becoming infected, and infecting others, with coronavirus (COVID-19). People in these groups may also be more...
Department of Health and Social Care (DHSC) has today granted the following initial list of price concessions: Drug Pack size Price Concession Aciclovir 400mg tablets 56 £3.44 Aciclovir 800mg tablets 35 £4.65 Amiloride 5mg tablets 28 £24.50 Amiodarone 200mg tablets 28 £2.90 Azathioprine 25mg tablets 28 £4.55 Azathioprine 50mg tablets 56 £5.30 Betahistine 16mg tablets...
How to show MHRA you're meeting good clinical practice (GCP) standards and what to expect from an inspection.
Monthly PDF editions of the Drug Safety Update newsletter from MHRA and its independent advisor the Commission on Human Medicines.
Reporting to the new site will enable the MHRA to rapidly identify new and emerging side effects and medical device incidents in COVID-19 treatment, including side effects for medicines taken by patients to manage long-term or pre-existing conditions.
Guidance has been published to support initiation of valproate in female patients and for annual review and pregnancy testing during the coronavirus pandemic.
Guidance has been published about thalidomide, lenalidomide, and pomalidomide and the use of remote consultations and home pregnancy testing for patients taking them during COVID-19.
A summary of letters and drug alerts recently sent to healthcare professionals.
How investigators and sponsors should manage clinical trials during COVID-19
Covering thalidomide, lenalidomide, and pomalidomide: temporary guidance for pregnancy prevention arrangements for patients taking them during COVID-19
Guidance for industry on flexible approaches to regulation we are taking during the COVID-19 outbreak.
Advice on writing clear notices and maximising replies to your FSNs.
Public list of companies in the UK who have had their licence/registration to manufacture or wholesale medicines/ingredients revoked or suspended.
The different types of tests and testing kits for COVID-19, and the specifications for manufacturers.
Guidance on how to get an e-cigarette on the market in the UK, including the notification scheme and reporting problems with e-cigarettes.
Allergy patients who carry Emerade 500 microgram adrenaline auto-injector pens should contact their prescriber and seek replacement pens of a different brand.
There are different regulations which apply to devices and equipment including hand gels and PPE (personal protective equipment)
Summary list of field safety notices (FSNs) from medical device manufacturers from 11 to 15 May 2020
Pharmaswiss Česka republika s.r.o. (an affiliate of Bausch & Lomb UK Limited) is recalling all unexpired batches of Emerade 500 microgram auto-injectors (also referred to as pens) from patients due to an error in one component of the auto-injector believed to cause some pens to fail to activate and deliver adrenaline.
Marketing authorisations granted in April 2020
Parallel import licenses granted in April 2020
To apply for a manufacturer licence, complete the appropriate form. Applications for a manufacturer licence will be payable on invoice.
Request to not send post to the VMD office.
Residues of veterinary medicines in food 2020 surveillance results.
Residues of veterinary medicines in food 2019 surveillance results.
The VMD virtual office will be closed on Monday 25 and Tuesday 26 May.
How to legally run a business that deals with the wholesale of animal medicines (veterinary medicinal products) and the WDA Register.
Marketing Authorisation Holders (MAHs) have informed the VMD of supply problems with the following lactating cow intramammary antibiotics.
For a marketing authorisation holder only; how to report a defect with a veterinary medicine.
Changes to exemptions from the Veterinary Medicines Regulations (VMR) for small pet animals (known as Schedule 6 exemptions).
How to comply with the exemption from the Veterinary Medicines Regulations that allow certain animal medicines to be sold without an authorisation.
Marketing Authorisations Information Service (MAVIS) Hub edition 114
News and guidance on veterinary medicines issues affected by coronavirus (COVID-19).
Reported problems with the supply of an animal medicine and the date when the issue is expected to be resolved.
Temporary change to the standard VMD guidance on Manufacturers of extemporaneous preparations for use under the cascade (ManSA).
Relaxation of enforcement during the coronavirus (COVID-19) outbreak.
Enforcement of Veterinary Medicines Regulations relaxed in light of enhanced precautions required by the response to coronavirus (COVID-19).
Relaxation of enforcement during the coronavirus (COVID-19) outbreak
Relaxation of enforcement during the coronavirus (COVID-19) outbreak.
Guidance on applying for an authorisation to manufacture veterinary medicines.
Statement on the availability of veterinary medicines during the coronavirus (COVID-19) outbreak.
Product defect recall alert for Foston 20% w/v Solution for Injection (Vm 01708/4426), by Intervet UK Ltd.
10 million tests have so far have been secured in a 'landmark deal' with industry, including Roche Diagnostics and Abbott Labs
The sites will be managed by the National Institute for Health Research (NIHR) and run by NHS trusts
Samsung will provide GSK with additional flexible capacity for large-scale biopharmaceutical product manufacturing
Tecentriq is the first and only immune checkpoint inhibitor which has been deemed a cost effective use of NHS resources for this patient group
The research will focus on people with psoriatic arthritis, axial spondyloarthritis and chronic pain conditions such as fibromyalgia
Over 130 UK frontline healthcare workers have lost their lives during the pandemic
The NHS Confederation is calling on the government for a clear strategy before lockdown measures are further lifted
Lynparza is the only PARP inhibitor to improve overall survival versus enzalutamide or abiraterone in prostate cancer patients with BRCA1/2 or ATM mutations
The overall death rate for people with diabetes doubled during the early stage of the pandemic
The deal could be worth 'several billions of dollars' to the US biotech
Research shows that a delay of three months across all 94,912 patients who would have had surgery to remove their cancer over one year would lead to an additional 4,755 deaths
Discussions with EU governments and reimbursement agencies are ongoing to agree on terms of an innovative 'Day One' access programme
The move is designed to accelerate the company's intelligent automation strategy
This is Tecentriq’s fourth indication in metastatic non-small cell lung cancer and fifth indication in lung cancer overall in the US
The proposals would enable pharmacists to amend the strength and formulation of the medicine dispensed or supply a generic alternative
Unit 2 Fleet Business Park, Sandy Lane, Church Crookham, Fleet, Hampshire, GU52 8BF
Pharmaceutical and Veterinary Licensed Distributor. WDA (H) 43703 & WDA (V) 43703.
- +44 (0)1252 260 460.
- +44 (0)1276 469 290
Monday to Friday - 09:30 – 18:30
Saturday & Sunday - Closed, Online Ordering Available
